

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-28 (Canceled).

Claim 29 (Currently Amended): A method of using a composition, for the preparation of a drug for the treatment of ~~the psychiatric disturbances of the central nervous system (CNS) selected from the group consisting~~ schizophrenia, manic-depressive syndrome, major depression, and Alzheimer's disease ~~comprising~~ consisting essentially of, a component selected from the group consisting of in a concentration expressed as % by weight of the total fatty acid weight in the composition, one selected from the group consisting of:

a) ~~alpha-linolenic acid (ALA, C18:3 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof;~~ ALA ethyl ester, wherein ALA ethyl ester is present in a concentration not lower than 70%;

b) ~~docosahexaenoic acid (DHA, C22:6 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof;~~ and DHA ethyl ester >30 and EPA ethyl ester >44, wherein EPA+DHA ethyl esters >80, the ethyl esters of other (C20, C21, C22) n-3 acids being >3; and

c) DHA ethyl ester >34 and EPA ethyl ester >40, wherein EPA+DHA ethyl esters >80, the total ethyl esters of n-3 acids being >90, in admixture with eicosapentaenoic acid (EPA,

~~C20:5 n-3), in a ratio of 1:0.5 to 1: 1.7, respectively, and/or the pharmaceutically acceptable derivatives and/or precursors thereof;~~

~~wherein said component is present in a concentration not lower than 70% by weight of the total fatty acids weight in the composition;~~

~~with the provisos that:~~

~~when the composition comprises b), arachidonic acid is not added thereto; and~~

~~when the composition comprises c), it does not comprise 10 to 40% by weight of reducing/antioxidant vitamins or provitamins.~~

Claims 30-31 (Canceled).

Claim 32 (Withdrawn): The method according to claim 29, wherein the manic-depressive syndrome and major depression include disorders of mood, behaviour and autonomic functions correlated to activity, sleep and appetite.

Claim 33 (Withdrawn): The method according to claim 29, wherein the Alzheimer's disease includes the various related forms of dementia.

Claims 34-41 (Canceled).

Claim 42 (Currently Amended): The method according to claim 29, wherein the drug ~~comprises~~ consists essentially of DHA ethyl ester and EPA ethyl ester.

Claim 43 (Previously Presented): The method according to claim 29, wherein the drug is administered by oral route.

Claim 44 (Previously Presented): The method according to claim 29, wherein the drug is in the form of soft gelatine capsules.

Claim 45 (Previously Presented): The method according to claim 29, wherein the drug is administered at the dose of 0.1-5 g/day.

Claim 46 (Previously Presented): The method according to claim 29, wherein the drug is administered at the dose of 0.3-3 g/day.

Claim 47 (Previously Presented): The method according to claim 29, wherein the drug is administered at the dose of 1-2 g/day.

Claim 48 (Currently Amended): The method according to claim 29, wherein the drug is administered separately, as a coadjuvant or an auxiliary drug, from at least another drug effective for the ~~prevention and/or treatment of the disturbances of CNS~~ schizophrenia.

Claim 49 (Currently Amended): ~~The method according to claim 29,~~ A method of using a composition, for the preparation of a drug for the treatment for schizophrenia, consisting

essentially of, in a concentration expressed as % by weight of the total fatty acid weight in the composition, one selected from the group consisting of: a) ALA ethyl ester, wherein ALA ethyl ester is present in a concentration not lower than 70%, b) DHA ethyl ester >30 and EPA ethyl ester >44, wherein EPA+DHA ethyl esters >80, the ethyl esters of other (C20, C21, C22) n-3 acids being >3, and c) DHA ethyl ester >34 and EPA ethyl ester >40, wherein EPA+DHA ethyl esters >80, the total ethyl esters of n-3 acids being >90; and wherein the drug comprises

at least another drug effective for the prevention and/or treatment of the disturbances of CNS schizophrenia.

Claim 50 (New): A method of using a composition, for the preparation of a drug for the treatment of schizophrenia, consisting essentially of, in a concentration expressed as % by weight of the total fatty acid weight in the composition, ALA ethyl ester,

wherein ALA ethyl ester is present in a concentration not lower than 70%.